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Abstract
Background
Little is known about patients with severe symptomatic aortic stenosis (AS) who receive
medical management despite evaluation at a heart valve treatment center.
Objective
We identified patient characteristics associated with medical management, physician-
reported reasons for selecting medical management, and patients’ perceptions of their
involvement and satisfaction with treatment selection.
Methods and results
Of 454 patients evaluated for AS at 9 established heart valve treatment centers from
December 12, 2013 to August 19, 2014, we included 407 with severe symptomatic AS.
Information was collected using medical record review and survey of patients and treating
physicians. Of 407 patients, 212 received transcatheter aortic valve replacement (TAVR),
124 received surgical aortic valve replacement (SAVR), and 71 received medical manage-
ment (no SAVR/TAVR). Thirty-day predicted mortality was higher in patients receiving
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TAVR (8.7%) or medical management (9.8%) compared with SAVR (3.4%) (P<0.001). Phy-
sician-reported reasons for medical management included patient preference (31.0%),
medical futility (19.7%), inoperability/anatomic infeasibility (11.3%), and inadequate vascu-
lar access (8.5%). Compared with patients receiving AVR, medically managed patients
were less likely to report that they received enough information about the pros and cons of
treatment options (P = 0.03), that their physicians involved them in treatment decisions
(P<0.001), and that final decisions were the right ones (P<0.001).
Conclusions
Patient preference was the most common physician-reported reason for selecting non-inva-
sive AS management, yet patients not undergoing AVR after valve center evaluation reported
being less likely to receive sufficient education about treatment options and more likely to feel
uncertain about final treatment decisions. Greater attention to shared decision making may
improve the experience of care for this vulnerable group of patients.
Introduction
In the current era of transcatheter aortic valve replacement (TAVR), older patients receiving
either TAVR or surgical aortic valve replacement (SAVR) for severe symptomatic aortic steno-
sis (AS) have been well characterized in terms of their risk profiles and outcomes. Pivotal clini-
cal trials have described patients with severe, inoperable AS and their outcomes from TAVR,
[1, 2] as well as patients at both high and intermediate surgical risk and their outcomes from
both TAVR and SAVR.[3–6] Results from published studies have been supplemented by data
from large registries[7–13] that have identified risk profiles, treatment approaches, and out-
comes associated with aortic valve replacement (AVR) in real-world settings.
In contrast, little is known about patients with severe symptomatic AS who do not undergo
AVR despite referral to a heart valve treatment center in the current era. Prior research on
“medically managed” patients with AS has focused on describing the natural history of AS,[14–
18] calculating the proportion of patients never referred for valve replacement,[19–24] and
understanding reasons for non-referral.[21–24] Much less is known about the characteristics of
patients receiving medical management despite referral for AVR, physicians’ rationales for
these decisions,[25] and patients’ experience with care. In particular, we do not know if patients
receiving medical management believe they have received sufficient education to inform deci-
sions about AVR or had sufficient opportunities to articulate and incorporate their personal val-
ues and preferences into their care plans, all of which are core elements of shared decision
making. We also do not know if these patients feel comfortable with medical management as a
final treatment decision. More information about patients who receive medical management
for severe symptomatic AS after valve center evaluation may identify multiple opportunities to
improve their care at valve treatment centers, such as with improved education about treatment
options, increased focus on effective implementation of shared decision making, and more opti-
mized utilization of palliative care services.
In pursuit of this information, we studied contemporary data from the American College of
Cardiology’s (ACC’s) educational and quality improvement initiative Championing Care for the
Patient with Aortic Stenosis. One component of the initiative was to characterize the current con-
text for AS care in the United States by surveying patients and their physicians at nine well-estab-
lished heart valve treatment centers. We hypothesized that this data would demonstrate that
Medically managed patient with severe AS
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patients receiving medical management after referral for AVR would have higher predicted mor-
tality risk with surgery than patients receiving TAVR or SAVR and would be more likely to report
deficiencies in core elements of shared decision making than patients receiving AVR. We also
hypothesized that the most common reasons reported by physicians for selection of medical man-
agement would include medical futility and anatomic contraindications to AVR rather than
patient preference.
Methods
Study population
Study patients were drawn from nine established heart valve treatment centers in the United
States that were participating in the ACC’s initiative Championing Care for the Patient with
Aortic Stenosis. The mission of this initiative was to empower members of the heart valve team
to appropriately assess, refer, and provide timely patient-centered interventions for older
patients with severe symptomatic AS. One component of the initiative involved characterizing
the contemporary context of care for AS using a set of surveys developed to gather information
from (1) patient participants who had been referred to, evaluated, and treated at participating
valve centers, (2) participants’ medical records, and (3) participants’ consulting valve center
physicians. Participating valve centers all met the following pre-specified criteria: (1) multidis-
ciplinary heart valve team in place for at least six months; (2) minimum of six TAVR proce-
dures completed each month; (3) participation in the Society of Thoracic Surgeons (STS)/
ACC Transcatheter Valve Therapy (TVT) registry; and (4) prior or current participation in a
TAVR clinical trial.
Each valve center was asked to recruit at least 60 patients referred for AS evaluation who
subsequently received TAVR, SAVR, or medical management. Those patients who received
medical management may have undergone balloon aortic valvuloplasty as a palliative proce-
dure. To be eligible for participation, patients had to meet the following criteria: (1) age 19
years or older; (2) referral to a participating valve treatment center for evaluation and treat-
ment of AS; (3) completion of TAVR, completion of SAVR, or decision made to receive medi-
cal management in the 18 months prior to study initiation; and (4) ability of the patient or his
or her caregiver designee to complete all survey questions online, by paper-based instrument,
or by verbal responses in person or by phone. Patients received no financial incentive for par-
ticipation. Data collection occurred between December 12, 2013 and August 19, 2014.
Data elements
A data coordinator at each valve center abstracted the medical record for each participating
patient using a standardized form that was matched to the treatment strategy (TAVR, SAVR,
or medical management). This form collected demographic information, past health history,
clinical status at the time of evaluation, and aortic valve measurements obtained on echocardi-
ography and/or cardiac catheterization. Data elements were modeled on the abstraction form
used by the STS/ACC TVT registry.
For patients receiving medical management, the coordinator also reviewed the medical
record and met with each patient’s consulting valve center physician to determine the reasons
why medical management was chosen. Potential reasons included (1) patient preference; (2)
medical futility due to a life expectancy of less than 12 months due to non-cardiac conditions,
as determined by the evaluating physician; (3) acute myocardial infarction in the past 30 days;
(4) contraindication to anti-thrombotic agents; (5) contraindication to TAVR due to insuffi-
cient vascular access or anatomic infeasibility of aortic annulus; and (6) other. The perceived
timeliness of the patient’s referral to the valve treatment center (too early, early, timely, late,
Medically managed patient with severe AS
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too late) was also determined based on review of the medical record and assessment by the
valve center physician.
All participating patients also responded to a survey that assessed their experience at the
valve treatment center. The survey included items that assessed patients’ (1) satisfaction with
their initial appointment and diagnostic tests (e.g., laboratory testing, echocardiogram, cardiac
catheterization); (2) belief that they received the necessary information to make decisions
around valve replacement; (3) belief that they were given the chance by valve center physicians
to articulate and incorporate their personal values and preferences into their care plan; and (4)
belief that the final decision about their treatment for AS was the right one. Responses were
collected using a Likert-type scale with the following choices: strongly disagree, disagree, nei-
ther agree nor disagree, agree, strongly agree, and don’t know or not applicable.
Data coordinators submitted the data for each patient into a secure, HIPAA-compliant,
online form and database that was managed by the ACC. The online form was programmed to
minimize missing data. Quality checks were performed regularly to identify and resolve all
missing and erroneous data.
Categorization of patients by treatment group
All patients were categorized as having received TAVR, SAVR, or medical management.
Patients were excluded from our analysis if any of the following were present: (1) the treating
physician characterized the timeliness of the consultation as too early; (2) the patient was
asymptomatic, had mild or moderate AS, or had symptoms primarily from a non-cardiac con-
dition; or (3) no reason besides “other” was given for the decision to pursue medical manage-
ment and the patient had not previously received balloon aortic valvuloplasty, calculated aortic
valve area was greater than 1 cm2, and mean aortic valve pressure gradient was less than 40
mm Hg.
Study outcomes
We examined the following outcomes among patients with severe symptomatic AS receiving
TAVR, SAVR, or medical management: (1) medical history and complexity, including STS-
predicted 30-day mortality rate; (2) physician-reported reasons for medical management (if
appropriate); and (3) patient-reported beliefs as to whether they had received sufficient educa-
tion to inform decisions about AVR and sufficient opportunities to articulate and incorporate
their personal values and preferences into their care plans.
Statistical analysis
We calculated summary statistics for categorical variables using frequencies and percentages.
We calculated summary statistics for continuous variables using means with standard devia-
tions and medians with interquartile ranges. To compare differences in statistics between
treatment groups, we used Wilcoxon rank-sum and Kruskal-Wallis tests for continuous vari-
ables and chi-square tests for categorical variables. When examining differences in patient
characteristics by treatment strategy, we used 3-way testing to compare TAVR, SAVR, and
medical management groups because of anticipated differences in risk profiles between
patients receiving TAVR and SAVR. When examining differences in shared decision making
by treatment strategy, we used 2-way testing to compare the combined TAVR/SAVR group
with the medical management group because our intent was to understand differences in
patient experience by the decision to undergo or not undergo definitive valve replacement. All
statistical tests were 2-sided, and statistical significance was defined by a P value of less than
Medically managed patient with severe AS
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0.05. Analyses were conducted using SAS version 9.4 (Cary, NC) at the Duke Clinical Research
Institute.
The ACC obtained Institutional Review Board approval for this study from Chesapeake
IRB. Each participating valve treatment center (Cedars-Sinai, Cleveland Clinic, Duke Univer-
sity, Emory Healthcare, Mayo Clinic, New York Presbyterian Hospital of Columbia University
Medical Center, the Heart Hospital at Baylor Plano, Saint Vincent Medical Group in Indianap-
olis, and Yale University) obtained Institutional Review Board approval for this study from its
own institutional IRB. Duke University obtained a second Institutional Review Board approval
from its own institutional IRB to support its role as the data analysis center for this study.
Results
This study included 454 patients evaluated for severe symptomatic AS from nine heart valve
treatment centers (enrollment numbers by center ranged from 34 to 61). Of 454 enrolled
patients, 212 (46.7%) underwent TAVR, 124 (27.3%) SAVR, and 118 (26.0%) medical manage-
ment. Of the 118 patients undergoing medical management, 47 (39.8%) were not felt to have
severe symptomatic AS and were therefore excluded from subsequent analyses. Specifically,
twenty patients were excluded because the treating physician characterized the consultation as
too early. An additional 20 were excluded because the patient was described as asymptomatic,
had mild or moderate AS, or had symptoms primarily from a non-cardiac condition. Seven
patients were excluded because no reason except “other” was given for the decision to pursue
medical management, the patient had not previously received balloon aortic valvuloplasty, cal-
culated aortic valve area was greater than 1 cm2, and mean aortic valve pressure gradient was
less than 40 mm Hg.
Characteristics of patients with severe symptomatic AS in TAVR, SAVR and medical man-
agement cohorts are shown in Table 1. Patients receiving medical management were more
likely than those who received SAVR or TAVR to have class IV heart failure (P = 0.003) and be
on home oxygen (P = 0.004). Patients receiving TAVR were more likely to have had previous
coronary artery bypass procedures (P<0.001). Mean left ventricular ejection fraction, mean
aortic valve pressure gradient, and mean aortic valve area were no different among treatment
groups. The STS-predicted 30-day mortality rate was higher in patients undergoing TAVR or
medical management compared to patients undergoing SAVR (P<0.001).
Physician-reported reasons for selecting medical management for patients with severe
symptomatic AS are presented in Fig 1. The most common reason was patient preference,
which was present in 31% of patients who received medical management after valve center
evaluation. Almost 20% of patients did not receive valve replacement because of physicians’
concerns of medical futility, and approximately 11% and 9% of patients did not receive TAVR
or SAVR because of inoperability/anatomic infeasibility or inadequate access for TAVR,
respectively. Notably, 14% of medically managed patients declined surgery in the hope that
access to TAVR would broaden in the future.
Data from patients’ self-reports on the presence of elements related to shared decision mak-
ing during valve center evaluation are presented in S1 Table. While the majority of patients
had favorable experiences during valve center evaluation, those receiving medical management
compared with AVR were less likely to believe that they had received the necessary informa-
tion to make decisions regarding valve replacement (Fig 2).
Medically managed patients were less likely to believe that heart valve physicians and staff
helped them better understand their AS (P = 0.01), less likely to believe that they were given
enough information about the pros and cons of each treatment option (P = 0.03), and less
likely to believe that their heart valve physicians involved them in decisions around treatment
Medically managed patient with severe AS
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(P<0.001). Patients receiving medical management were also less likely to believe that the final
treatment decision was the right one for them (P<0.001). In particular, only 69% of patients
receiving medical management agreed or strongly agreed that this treatment course was the
right one for them, whereas over 95% of patients receiving TAVR or SAVR agreed or strongly
agreed that the decision to pursue definitive valve replacement was the correct one.
Discussion
This study is unique in characterizing patient-centered outcomes among patients with severe
symptomatic AS who were evaluated at a heart valve treatment center, but did not receive
either TAVR or SAVR. Our findings demonstrate that such patients have significant medical
complexity and frequent medical and technical contraindications to valve replacement. While
the majority of patients had favorable experiences during valve center evaluation, those receiv-
ing medical management were less likely to report receiving sufficient information to support
the decision for medical management, less likely to feel that their heart valve doctors involved
them in treatment decisions, and less likely to believe that the final decision was the right one
Table 1. Characteristics of patients receiving transcatheter aortic valve replacement, surgical aortic valve replacement, and medical management
for severe symptomatic aortic stenosis.
Patient Characteristic TAVR Cohort (N = 212) SAVR Cohort (N = 124) Medical Management Cohort
(N = 71)
P Value
Demographics
Mean age in years (SD) 80.7 (8.6) 73.2 (9.5) 82.6 (8.6) <0.001
Male gender (%) 57.6 65.3 47.9 0.06
White race (%) 96.7 96.0 93.0 0.39
Black race (%) 2.8 2.4 4.2 0.77
Cardiac history
Prior MI (%) 21.2 8.9 19.7 0.01
Prior PCI (%) 32.6 19.4 18.3 0.008
Prior CABG %) 40.6 6.5 22.5 <0.001
Prior aortic valve procedure (%) 10.9 2.4 7.0 0.02
NYHA class 3 (%) 50.0 31.5 38.0 0.003
NYHA class 4 (%) 30.2 17.7 39.4 0.003
Mean LVEF, in % (SD) 53.9 (12.5) 56.2 (10.7) 51.5 (15.3) 0.20
Mean AV pressure gradient in mm Hg (SD) 45.4 (13.0) 44.6 (13.9) 41.2 (13.8) 0.12
Mean AV area in cm2 (SD) 0.7 (0.2) 0.8 (0.2) 0.7 (0.2) 0.07
Non-cardiac history
Prior stroke (%) 10.8 5.7 14.1 0.13
Peripheral arterial disease (%) 44.3 17.7 31.0 <0.001
Diabetes mellitus (%) 39.2 33.1 39.4 0.50
End-stage renal disease (%) 2.4 2.4 7.0 0.13
Moderate or severe chronic lung disease (%) 32.6 12.9 31.0 <0.001
On home oxygen (%) 15.1 4.8 19.7 0.004
Mean serum creatinine in mg/dL (SD) 1.3 (0.7) 1.2 (1.2) 1.6 (1.6) 0.43
Mean STS 30-day predicted mortality rate (%)
(SD)
8.7 (4.5) 3.4 (2.4) 9.8 (6.4) <0.001
AV, aortic valve; CABG, coronary artery bypass grafting; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart
Association; PCI, percutaneous coronary intervention; SAVR, surgical aortic valve replacement; SD, standard deviation; STS, Society of Thoracic
Surgeons; TAVR, transcatheter aortic valve replacement.
https://doi.org/10.1371/journal.pone.0175926.t001
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for them. Overall, these results suggest a potential gap in care that may benefit from additional
efforts to enhance communication between patients and physicians.
Interventional cardiologists and cardiac surgeons who are poised to deliver AVR may not
always be skilled in shared decision making and alternative treatment modalities, including
palliative care. To promote enhanced communication, valve centers may consider supple-
menting their current interactions with patients with (1) in-visit decision aids designed to
increase collaborative discussions with providers; (2) educational material focused on medical
management, such as tailored after-visit summaries that explain the rationale for not selecting
AVR; and (3) video presentations that review potential risks of treatment that may result in
further suffering. Such tools have been used to facilitate discussions around cardiopulmonary
resuscitation.[26, 27] While it is true that disappointment in the final recommendation against
AVR may influence some patients’ perceptions of their valve center experience, feelings of
frustration and exclusion are real. Additional engagement and time discussing treatment alter-
natives and priorities may improve the degree to which patients feel that their goals, values,
and preferences are sufficiently understood and acknowledged.[28] In addition, further
Fig 1. Reasons for medical management among patients with severe symptomatic aortic stenosis (AS). The total number of articulated reasons was
divided by the number of included patients (n = 71), as patients could have more than one reason for medical management. AV indicates aortic valve; BAV,
balloon aortic valvuloplasty; MI, myocardial infarction; and TAVR, transcatheter aortic valve replacement.
https://doi.org/10.1371/journal.pone.0175926.g001
Medically managed patient with severe AS
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attention to patients’ emotional responses may improve their satisfaction with communica-
tion.[29] These emotional reactions can be just as important to address as more cognitive
responses.[29] While previous work has shown that patients’ emotional concerns are often
unrecognized and unaddressed,[30, 31] intensive communication skills training using role
playing in small groups can help physicians of multiple disciplines provide better emotional
support to patients who receive bad news or a recommendation for palliative care.[32–35]
As more than one in three patients did not receive AVR due to anatomic contraindications
or a high competing risk of death from other medical conditions, it is likely that many patients
will benefit from palliative care consultation. Palliative care is a recommended component of
care for medically managed symptomatic AS[36, 37] that can provide supportive resources to
help patients understand the expected course of disease, recognize their concerns and fears,
discuss spiritual and existential needs, and develop plans for symptom management as disease
progresses.[38–40] Palliative care consultation can also help stimulate advanced care planning
and goal setting in which patients “hope for the best but plan for the worst.”[38] Valve treat-
ment centers may therefore consider developing internal palliative care resources to start pre-
liminary discussions with all patients for whom a decision is made to forgo valve replacement
Fig 2. Quality of knowledge transfer, patient engagement, and shared decision making by aortic valve treatment strategy. Bar charts compare
responses of “agree” or “strongly agree” to study questions between participants who did and did not receive aortic valve replacement. AS, aortic stenosis;
SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.
https://doi.org/10.1371/journal.pone.0175926.g002
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[41] and may also consider developing relationships with outpatient palliative care providers
who can provide more comprehensive services.
This study draws attention to the larger group of patients with advanced cardiovascular dis-
ease who do not undergo potentially life-saving or palliative procedures for which they have
been evaluated. Cardiologists and cardiothoracic surgeons see many such individuals, including
those with pronounced angina who are not candidates for complex revascularization procedures
and patients with advanced heart failure who are not candidates for heart transplant or a ventric-
ular assist device. Currently, no registries have been established to study the experiences of these
patients during and after consultation. Patients with cardiovascular disease may be especially
likely to experience suboptimal end of life care compared with persons with cancer and demen-
tia.[42] Due to their significant patient volume, large referral centers are in an ideal position to
advance our knowledge of these medically managed patients and can facilitate prospective obser-
vational studies and clinical trials to better characterize patient phenotypes, disease progression,
and responses to various interventions to help improve important outcomes such as symptom
burden, functional status, independence, and health-related quality of life.[43, 44]
Our results should be interpreted in the context of the following limitations. First, our
study is unique in collecting patient perspectives on referral outcomes, but is based on a rela-
tively small sample size drawn from nine leading heart valve treatment centers that may not
provide care that is broadly generalizable. However, our finding of deficiencies in information
transfer and core elements related to shared decision making at these established centers sug-
gests that these gaps in care may be widespread. Second, our study population was not ran-
domly selected. However, the population that was enrolled likely biased results to the null, as
medically managed patients who were well enough to participate in our study should have
been less likely to have high risk features and multiple contraindications to valve replacement.
Third, we did not follow medically managed patients to define disease progression, as this was
not our goal. Our intent was to describe the characteristics of patients with severe symptomatic
AS at the time of valve center evaluation, understand the reasons why medical management is
most often pursued, and characterize these patients’ experience of care around the decision to
forgo valve replacement. As a result, we interviewed patients and their treating physicians to
better understand complexities associated with evaluation and management. Fourth, survey
results of medically managed patients on the quality of interactions during valve center evalua-
tion may be disproportionally biased by dissatisfaction with the treatment decision.
In summary, we found that patients receiving medical management for severe symptomatic
AS after referral to a heart valve treatment center are medically complex and frequently have
contraindications to TAVR and SAVR. While physicians report patient preference as the most
common reason to select medical management, we observed that patients receiving medical
management are less likely to report receiving sufficient information to make decisions around
valve replacement, less likely feel engaged by their heart valve physicians in treatment deci-
sions, and less likely to believe that the final decision was the appropriate one. Additional
investment in patient education and engagement, provider training, and palliative care ser-
vices may help improve patients’ experience during and after valve center evaluation.
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